Research programme: cartilage disorder therapies - OmerosAlternative Names: Chondroprotective
Latest Information Update: 16 Jul 2016
At a glance
- Originator Omeros Corporation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cartilage disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cartilage-disorders in USA
- 14 Aug 2009 Preclinical trials in Cartilage disorders in USA (unspecified route)